Prihlásiť sa Zaregistrujte sa zadarmo

Last updated: 28 July 2023 at 6:40pm EST

David Anderson Net Worth



David Anderson biography

Dr. David E. Anderson Ph.D. serves as Chief Scientific Officer of the Company. Dr. Anderson has served as our Chief Scientific Officer since May 6, 2016 and as VBI DE’s Chief Scientific Officer since August 2015 and as VBI US’s Vice President of Immunology/Research since joining VBI US full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. Dr. Anderson is an immunologist with expertise in the areas of vaccine development, autoimmunity and tumor immunology. As a co-founder of Variation Biotechnologies Inc. a Canadian company and the wholly-owned subsidiary of VBI US (“VBI Cda”), Dr. Anderson is an inventor on many of VBI’s patents and actively manages VBI’s research operation. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California, Davis.

What is the salary of David Anderson?

As the Chief Scientific Officer of VBI Vaccines, the total compensation of David Anderson at VBI Vaccines is $881,700. There are 3 executives at VBI Vaccines getting paid more, with Jeffrey Baxter having the highest compensation of $1,379,630.



How old is David Anderson?

David Anderson is 50, he's been the Chief Scientific Officer of VBI Vaccines since 2016. There are 14 older and 5 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.

What's David Anderson's mailing address?

David's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.

Insiders trading at VBI Vaccines

Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv a Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.



What does VBI Vaccines do?

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.



What does VBI Vaccines's logo look like?

VBI Vaccines Inc. logo

VBI Vaccines executives and stock owners

VBI Vaccines executives and other stock owners filed with the SEC include: